# A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

> **NCT05592275** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 332 (actual)

## Conditions studied

- Heart Failure
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** LY3540378
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05592275
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-03
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-01-22
- **Target enrollment:** 332 (ACTUAL)
- **Why stopped:** An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population.
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05592275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05592275, "A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05592275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*